
|Videos|January 25, 2018
Dr. Goetz Discusses a Secondary Analysis of the MONARCH Trials in Breast Cancer
Author(s)Matthew Goetz, MD
Matthew Goetz, MD, professor of oncology and pharmacology, Mayo Clinic, discusses a secondary analysis of the MONARCH 1 and MONARCH 2 clinical trials in breast cancer.
Advertisement
Matthew Goetz, MD, professor of oncology and pharmacology, Mayo Clinic, discusses a secondary analysis of the MONARCH 1 and MONARCH 2 clinical trials in breast cancer.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
3
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
4
HRT Shows No Adverse Effect on Breast Cancer Risk in Patients With BRCA Variant
5







































